Ubs Group Ag Adaptive Biotechnologies Corp Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Adaptive Biotechnologies Corp stock. As of the latest transaction made, Ubs Group Ag holds 275,617 shares of ADPT stock, worth $2.62 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

275,617

Previous 397,258 30.62%

Holding current value

$2.62 Million

Previous $2.38 Million 14.1%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	SELL	$6.07 - $8.66 $738,360 - $1.05 Million	-121,641 Reduced 30.62%	275,617 $2.05 Million
Q4 2024 Feb 14, 2025	BUY	$4.37 - $6.78 $1.42 Million - $2.2 Million	324,107 Added 443.07%	397,258 $2.38 Million
Q3 2024 Nov 14, 2024	BUY	$3.37 - $5.12 $55,672 - $84,582	16,520 Added 29.17%	73,151 $374,000
Q2 2024 Aug 13, 2024	SELL	$2.34 - $3.96 $203,542 - $344,456	-86,984 Reduced 60.57%	56,631 $205,000
Q1 2024 May 13, 2024	BUY	$2.88 - $4.8 $31,953 - $53,256	11,095 Added 8.37%	143,615 $461,000
Q4 2023 Feb 09, 2024	BUY	$3.46 - $5.33 $146,018 - $224,936	42,202 Added 46.73%	132,520 $649,000
Q3 2023 Nov 09, 2023	SELL	$5.07 - $8.44 $60,956 - $101,474	-12,023 Reduced 11.75%	90,318 $492,000
Q2 2023 Aug 11, 2023	BUY	$6.19 - $8.78 $95,839 - $135,940	15,483 Added 17.83%	102,341 $686,000
Q1 2023 May 12, 2023	BUY	$7.8 - $10.11 $192,831 - $249,939	24,722 Added 39.79%	86,858 $766,000
Q4 2022 Feb 08, 2023	BUY	$6.26 - $9.34 $219,920 - $328,123	35,131 Added 130.09%	62,136 $474,000
Q3 2022 Nov 10, 2022	BUY	$6.5 - $12.67 $11,212 - $21,855	1,725 Added 6.82%	27,005 $193,000
Q2 2022 Aug 10, 2022	SELL	$6.4 - $14.73 $155,980 - $358,999	-24,372 Reduced 49.09%	25,280 $205,000
Q1 2022 May 16, 2022	BUY	$10.12 - $28.9 $505 - $1,445	50 Added 0.1%	49,652 $690,000
Q4 2021 Feb 14, 2022	SELL	$25.17 - $36.85 $61,817 - $90,503	-2,456 Reduced 4.72%	49,602 $1.39 Million
Q3 2021 Nov 15, 2021	BUY	$30.02 - $39.87 $1.1 Million - $1.47 Million	36,761 Added 240.32%	52,058 $1.77 Million
Q2 2021 Aug 13, 2021	SELL	$32.22 - $44.59 $215,358 - $298,039	-6,684 Reduced 30.41%	15,297 $625,000
Q1 2021 May 12, 2021	SELL	$37.26 - $67.74 $36,738 - $66,791	-986 Reduced 4.29%	21,981 $885,000
Q4 2020 Feb 11, 2021	SELL	$45.01 - $65.47 $167,032 - $242,959	-3,711 Reduced 13.91%	22,967 $1.36 Million
Q3 2020 Nov 12, 2020	BUY	$35.79 - $48.81 $131,206 - $178,937	3,666 Added 15.93%	26,678 $1.3 Million
Q2 2020 Jul 31, 2020	SELL	$24.95 - $48.38 $92,464 - $179,296	-3,706 Reduced 13.87%	23,012 $1.11 Million
Q1 2020 May 01, 2020	BUY	$16.96 - $34.16 $284,724 - $573,478	16,788 Added 169.06%	26,718 $742,000
Q4 2019 Feb 14, 2020	SELL	$24.56 - $32.8 $54,302 - $72,520	-2,211 Reduced 18.21%	9,930 $297,000
Q3 2019 Nov 14, 2019	BUY	$30.31 - $53.51 $367,993 - $649,664	12,141 New	12,141 $375,000

Others Institutions Holding ADPT

# of Institutions

246

Shares Held

156M

Call Options Held

44.3K

Put Options Held

47.8K

View Full List

About Adaptive Biotechnologies Corp

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $1.36B
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

More about ADPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account